Last 12 months
Inside the activity.
0 purchase rows · 14 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 8 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 4 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 02, 2024 Filed Aug 7, 2024 00:00 UTC |
Mandalam RamkumarDirector
|
SaleCommon Stock | 4,167 | $8.04 | $33,520.18 |
DisclosureSEC source: 0001104659-24-086387 · tm2421024-1_4seq1.xml · nonDerivative · entry 2 Mandalam Ramkumar · CIK 0001611439 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,032 F1 · kind: The transactions reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.80 to $8.29, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 02, 2024 Filed Aug 7, 2024 00:00 UTC |
Mandalam RamkumarDirector
|
Exercise / conversionCommon Stock | 4,167 | $5.04 | $21,001.68 |
DisclosureSEC source: 0001104659-24-086387 · tm2421024-1_4seq1.xml · nonDerivative · entry 1 Mandalam Ramkumar · CIK 0001611439 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024. Read SEC document |
| May 17, 2024 Filed May 21, 2024 19:00 UTC |
BERMAN RICHARD JDirector
|
GrantOption (Right to Buy Common Stock) · Derivative | 23,830 | $0.00 Strike: $12.65 | $0.00 |
DisclosureSEC source: 0001104659-24-063961 · tm2415098-1_4seq1.xml · derivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,830 Underlying: Common Stock · 23,830 shares Expires 2031-05-17 F2 · derivative.exercise_date: 1/12th of the options vest on the 17th of the month for twelve months beginning June 17, 2024. Read SEC document |
| May 17, 2024 Filed May 21, 2024 19:00 UTC |
BERMAN RICHARD JDirector
|
GrantCommon Stock | 12,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-063961 · tm2415098-1_4seq1.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,845 F1 · security: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| May 17, 2024 Filed May 21, 2024 23:02 UTC |
BADDOUR LINDADirector
|
GrantOption (Right to Buy Common Stock) · Derivative | 23,830 | $0.00 Strike: $12.65 | $0.00 |
DisclosureSEC source: 0001104659-24-063966 · tm2415098-4_4seq1.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,830 Underlying: Common Stock · 23,830 shares Expires 2031-05-17 F2 · derivative.exercise_date: 1/12th of the options vest on the 17th of the month for twelve months beginning June 17, 2024. Read SEC document |
| May 17, 2024 Filed May 21, 2024 23:02 UTC |
BADDOUR LINDADirector
|
GrantCommon Stock | 12,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-063966 · tm2415098-4_4seq1.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,535 F1 · security: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| May 17, 2024 Filed May 21, 2024 23:03 UTC |
Mandalam RamkumarDirector
|
GrantOption (Right to Buy Common Stock) · Derivative | 23,830 | $0.00 Strike: $12.65 | $0.00 |
DisclosureSEC source: 0001104659-24-063968 · tm2415098-5_4seq1.xml · derivative · entry 2 Mandalam Ramkumar · CIK 0001611439 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,830 Underlying: Common Stock · 23,830 shares Expires 2031-05-17 F2 · derivative.exercise_date: 1/12th of the options vest on the 17th of the month for twelve months beginning June 17, 2024. Read SEC document |
| May 17, 2024 Filed May 21, 2024 23:03 UTC |
Mandalam RamkumarDirector
|
GrantCommon Stock | 12,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-063968 · tm2415098-5_4seq1.xml · nonDerivative · entry 1 Mandalam Ramkumar · CIK 0001611439 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,032 F1 · security: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| May 17, 2024 Filed May 21, 2024 23:01 UTC |
Hariri Robert JDirector
|
GrantOption (Right to Buy Common Stock) · Derivative | 23,830 | $0.00 Strike: $12.65 | $0.00 |
DisclosureSEC source: 0001104659-24-063964 · tm2415098-3_4seq1.xml · derivative · entry 2 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,830 Underlying: Common Stock · 23,830 shares Expires 2031-05-17 F2 · derivative.exercise_date: 1/12th of the options vest on the 17th of the month for twelve months beginning June 17, 2024. Read SEC document |
| May 17, 2024 Filed May 21, 2024 23:01 UTC |
Hariri Robert JDirector
|
GrantCommon Stock | 12,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-063964 · tm2415098-3_4seq1.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,561 F1 · security: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| May 17, 2024 Filed May 21, 2024 23:01 UTC |
HANCOCK DANIEL MDirector
|
GrantOption (Right to Buy Common Stock) · Derivative | 23,830 | $0.00 Strike: $12.65 | $0.00 |
DisclosureSEC source: 0001104659-24-063963 · tm2415098-2_4seq1.xml · derivative · entry 2 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,830 Underlying: Common Stock · 23,830 shares Expires 2031-05-17 F2 · derivative.exercise_date: 1/12th of the options vest on the 17th of the month for twelve months beginning June 17, 2024. Read SEC document |
| May 17, 2024 Filed May 21, 2024 23:01 UTC |
HANCOCK DANIEL MDirector
|
GrantCommon Stock | 12,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-063963 · tm2415098-2_4seq1.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,488 F1 · security: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| May 15, 2024 Filed May 16, 2024 17:30 UTC |
BERMAN RICHARD JDirector
|
SaleCommon Stock | 8,105 | $13.41 | $108,692.91 |
DisclosureSEC source: 0001104659-24-062629 · tm2414776-1_4seq1.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.305 to $13.675, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 14, 2024 Filed May 15, 2024 23:28 UTC |
ZECCHINI EDWARD JChief Digital and Tech Officer
|
SaleCommon Stock | 3,443 | $13.37 | $46,042.21 |
DisclosureSEC source: 0001104659-24-062114 · tm2414667-1_4seq1.xml · nonDerivative · entry 1 ZECCHINI EDWARD J · CIK 0001587502 · Chief Digital and Tech Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,051 F1 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 00:12 UTC |
STEFANOVICH ROBERTChief Financial Officer
|
SaleCommon Stock | 1,079 | $17.54 | $18,928.14 |
DisclosureSEC source: 0001104659-24-039195 · tm249900-3_4seq1.xml · nonDerivative · entry 1 STEFANOVICH ROBERT · CIK 0001247309 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,333 F1 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 00:09 UTC |
SHELTON JERRELLDirector · Chief Executive Officer
|
SaleCommon Stock | 2,631 | $17.54 | $46,153.79 |
DisclosureSEC source: 0001104659-24-039194 · tm249900-2_4seq1.xml · nonDerivative · entry 1 SHELTON JERRELL · CIK 0001283212 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 692,182 F1 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 00:08 UTC |
Sawicki Mark WChief Scientific Officer
|
SaleCommon Stock | 1,367 | $17.54 | $23,980.32 |
DisclosureSEC source: 0001104659-24-039193 · tm249900-1_4seq1.xml · nonDerivative · entry 1 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,444 F1 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:52 UTC |
ZECCHINI EDWARD JChief Digital and Tech Officer
|
GrantStock Option (right to buy) · Derivative | 20,910 | $0.00 Strike: $16.70 | $0.00 |
DisclosureSEC source: 0001104659-24-036290 · tm249281-6_4seq1.xml · derivative · entry 2 ZECCHINI EDWARD J · CIK 0001587502 · Chief Digital and Tech Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,910 Underlying: Common Stock · 20,910 shares Expires 2031-03-15 F2 · derivative.exercise_date: 1/48 of options vest on the 15th of each month for forty-eight months beginning April 25, 2024. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:52 UTC |
ZECCHINI EDWARD JChief Digital and Tech Officer
|
GrantCommon Stock | 10,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-036290 · tm249281-6_4seq1.xml · nonDerivative · entry 1 ZECCHINI EDWARD J · CIK 0001587502 · Chief Digital and Tech Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,494 F1 · security: Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 15, 2025. F1 · price: Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 15, 2025. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:51 UTC |
STEFANOVICH ROBERTChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 11,500 | $0.00 Strike: $16.70 | $0.00 |
DisclosureSEC source: 0001104659-24-036286 · tm249281-5_4seq1.xml · derivative · entry 6 STEFANOVICH ROBERT · CIK 0001247309 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2031-03-15 F5 · derivative.exercise_date: 1/48 of options vest on the 15th of each month for forty-eight months beginning April 25, 2024. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:51 UTC |
STEFANOVICH ROBERTChief Financial Officer
|
GrantCommon Stock | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-036286 · tm249281-5_4seq1.xml · nonDerivative · entry 4 STEFANOVICH ROBERT · CIK 0001247309 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,412 F3 · security: Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 15, 2025. F3 · price: Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 15, 2025. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:51 UTC |
STEFANOVICH ROBERTChief Financial Officer
|
SaleCommon Stock | 1,035 | $15.43 | $15,972.33 |
DisclosureSEC source: 0001104659-24-036286 · tm249281-5_4seq1.xml · nonDerivative · entry 3 STEFANOVICH ROBERT · CIK 0001247309 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,662 F2 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:50 UTC |
Sawicki Mark WChief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 11,500 | $0.00 Strike: $16.70 | $0.00 |
DisclosureSEC source: 0001104659-24-036284 · tm249281-4_4seq1.xml · derivative · entry 6 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2031-03-15 F5 · derivative.exercise_date: 1/48 of options vest on the 15th of each month for forty-eight months beginning April 25, 2024. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:50 UTC |
Sawicki Mark WChief Scientific Officer
|
GrantCommon Stock | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-036284 · tm249281-4_4seq1.xml · nonDerivative · entry 4 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,811 F3 · security: Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 15, 2025. F3 · price: Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 15, 2025. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:50 UTC |
Sawicki Mark WChief Scientific Officer
|
SaleCommon Stock | 1,312 | $15.43 | $20,247.05 |
DisclosureSEC source: 0001104659-24-036284 · tm249281-4_4seq1.xml · nonDerivative · entry 3 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,061 F2 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:49 UTC |
Mandalam RamkumarDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 8,334 | $0.00 Strike: $5.40 | $0.00 |
DisclosureSEC source: 0001104659-24-036283 · tm249281-3_4seq1.xml · derivative · entry 3 Mandalam Ramkumar · CIK 0001611439 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,334 shares Expires 2024-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:49 UTC |
Mandalam RamkumarDirector
|
SaleCommon Stock | 3,217 | $14.68 | $47,225.56 |
DisclosureSEC source: 0001104659-24-036283 · tm249281-3_4seq1.xml · nonDerivative · entry 2 Mandalam Ramkumar · CIK 0001611439 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,187 Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:49 UTC |
Mandalam RamkumarDirector
|
Exercise / conversionCommon Stock | 8,334 | $5.40 | $45,003.60 |
DisclosureSEC source: 0001104659-24-036283 · tm249281-3_4seq1.xml · nonDerivative · entry 1 Mandalam Ramkumar · CIK 0001611439 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:48 UTC |
BADDOUR LINDADirector
|
Exercise / conversionRestricted Stock Rights · Derivative | 1,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-036282 · tm249281-2_4seq1.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The originally granted restricted stock rights vest in three equal annual installments beginning March 15, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 15, 2024. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F2 · derivative.exercise_date: The originally granted restricted stock rights vest in three equal annual installments beginning March 15, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 15, 2024. F2 · derivative.expiration_date: The originally granted restricted stock rights vest in three equal annual installments beginning March 15, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 15, 2024. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:48 UTC |
BADDOUR LINDADirector
|
Exercise / conversionCommon Stock | 1,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-036282 · tm249281-2_4seq1.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F1 · price: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:48 UTC |
SHELTON JERRELLDirector · President, CEO
|
GrantStock Option (right to buy) · Derivative | 33,524 | $0.00 Strike: $16.70 | $0.00 |
DisclosureSEC source: 0001104659-24-036281 · tm249281-1_4seq1.xml · derivative · entry 9 SHELTON JERRELL · CIK 0001283212 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,524 Underlying: Common Stock · 33,524 shares Expires 2031-03-15 F7 · derivative.exercise_date: 1/48 of options vest on the 15th of each month for forty-eight months beginning April 25, 2024. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:48 UTC |
SHELTON JERRELLDirector · President, CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001104659-24-036281 · tm249281-1_4seq1.xml · derivative · entry 8 SHELTON JERRELL · CIK 0001283212 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,167 Underlying: Common Stock · 100,000 shares Expires 2024-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/48 of the options vested on the 18th of each month for forty-eight months beginning on January 18, 2015. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:48 UTC |
SHELTON JERRELLDirector · President, CEO
|
SaleCommon Stock | 54,440 | $15.04 | $818,853.82 |
DisclosureSEC source: 0001104659-24-036281 · tm249281-1_4seq1.xml · nonDerivative · entry 6 SHELTON JERRELL · CIK 0001283212 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 694,813 F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.84 to $15.28, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:48 UTC |
SHELTON JERRELLDirector · President, CEO
|
Exercise / conversionCommon Stock | 100,000 | $4.80 | $480,000.00 |
DisclosureSEC source: 0001104659-24-036281 · tm249281-1_4seq1.xml · nonDerivative · entry 5 SHELTON JERRELL · CIK 0001283212 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 749,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:48 UTC |
SHELTON JERRELLDirector · President, CEO
|
GrantCommon Stock | 14,901 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-036281 · tm249281-1_4seq1.xml · nonDerivative · entry 4 SHELTON JERRELL · CIK 0001283212 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 649,253 F3 · security: Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 15, 2025. F3 · price: Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 15, 2025. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:48 UTC |
SHELTON JERRELLDirector · President, CEO
|
SaleCommon Stock | 2,599 | $20.79 | $54,030.61 |
DisclosureSEC source: 0001104659-24-036281 · tm249281-1_4seq1.xml · nonDerivative · entry 3 SHELTON JERRELL · CIK 0001283212 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 634,352 F2 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. Read SEC document |
| March 11, 2024 Filed Mar 19, 2024 23:51 UTC |
STEFANOVICH ROBERTChief Financial Officer
|
SaleCommon Stock | 1,119 | $16.35 | $18,298.34 |
DisclosureSEC source: 0001104659-24-036286 · tm249281-5_4seq1.xml · nonDerivative · entry 2 STEFANOVICH ROBERT · CIK 0001247309 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,697 F2 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. Read SEC document |
| March 11, 2024 Filed Mar 19, 2024 23:50 UTC |
Sawicki Mark WChief Scientific Officer
|
SaleCommon Stock | 1,418 | $16.35 | $23,187.70 |
DisclosureSEC source: 0001104659-24-036284 · tm249281-4_4seq1.xml · nonDerivative · entry 2 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,373 F2 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. Read SEC document |
| March 11, 2024 Filed Mar 19, 2024 23:48 UTC |
SHELTON JERRELLDirector · President, CEO
|
SaleCommon Stock | 3,723 | $16.35 | $60,879.99 |
DisclosureSEC source: 0001104659-24-036281 · tm249281-1_4seq1.xml · nonDerivative · entry 2 SHELTON JERRELL · CIK 0001283212 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 636,951 F2 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. Read SEC document |
| March 09, 2024 Filed Mar 19, 2024 23:51 UTC |
STEFANOVICH ROBERTChief Financial Officer
|
Exercise / conversionRestricted Stock Rights · Derivative | 2,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-036286 · tm249281-5_4seq1.xml · derivative · entry 5 STEFANOVICH ROBERT · CIK 0001247309 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,667 Underlying: Common Stock · 2,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The originally granted restricted stock rights vest in four equal annual installments beginning March 9, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2024. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F4 · derivative.exercise_date: The originally granted restricted stock rights vest in four equal annual installments beginning March 9, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2024. F4 · derivative.expiration_date: The originally granted restricted stock rights vest in four equal annual installments beginning March 9, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2024. Read SEC document |
| March 09, 2024 Filed Mar 19, 2024 23:51 UTC |
STEFANOVICH ROBERTChief Financial Officer
|
Exercise / conversionCommon Stock | 2,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-036286 · tm249281-5_4seq1.xml · nonDerivative · entry 1 STEFANOVICH ROBERT · CIK 0001247309 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F1 · price: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. Read SEC document |
| March 09, 2024 Filed Mar 19, 2024 23:50 UTC |
Sawicki Mark WChief Scientific Officer
|
Exercise / conversionRestricted Stock Rights · Derivative | 2,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-036284 · tm249281-4_4seq1.xml · derivative · entry 5 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,667 Underlying: Common Stock · 2,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The originally granted restricted stock rights vest in four equal annual installments beginning March 9, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2024. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F4 · derivative.exercise_date: The originally granted restricted stock rights vest in four equal annual installments beginning March 9, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2024. F4 · derivative.expiration_date: The originally granted restricted stock rights vest in four equal annual installments beginning March 9, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2024. Read SEC document |
| March 09, 2024 Filed Mar 19, 2024 23:50 UTC |
Sawicki Mark WChief Scientific Officer
|
Exercise / conversionCommon Stock | 2,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-036284 · tm249281-4_4seq1.xml · nonDerivative · entry 1 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F1 · price: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. Read SEC document |
| March 09, 2024 Filed Mar 19, 2024 23:48 UTC |
SHELTON JERRELLDirector · President, CEO
|
Exercise / conversionRestricted Stock Rights · Derivative | 8,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-036281 · tm249281-1_4seq1.xml · derivative · entry 7 SHELTON JERRELL · CIK 0001283212 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,250 Underlying: Common Stock · 8,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The originally granted restricted stock rights vest in four equal annual installments beginning 3/9/2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2024. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F5 · derivative.exercise_date: The originally granted restricted stock rights vest in four equal annual installments beginning 3/9/2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2024. F5 · derivative.expiration_date: The originally granted restricted stock rights vest in four equal annual installments beginning 3/9/2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2024. Read SEC document |
| March 09, 2024 Filed Mar 19, 2024 23:48 UTC |
SHELTON JERRELLDirector · President, CEO
|
Exercise / conversionCommon Stock | 8,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-036281 · tm249281-1_4seq1.xml · nonDerivative · entry 1 SHELTON JERRELL · CIK 0001283212 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 640,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F1 · price: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. Read SEC document |
| December 14, 2023 Filed Dec 19, 2023 00:19 UTC |
Hariri Robert JDirector
|
SaleCommon Stock | 800 | $16.89 | $13,512.00 |
DisclosureSEC source: 0001104659-23-127005 · tm2333196-1_4seq1.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,716 Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 23:02 UTC |
Hariri Robert JDirector
|
SaleCommon Stock | 1,000 | $15.50 | $15,500.00 |
DisclosureSEC source: 0001104659-23-125791 · tm2332860-1_4seq1.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,516 Read SEC document |
| September 12, 2023 Filed Sep 13, 2023 21:01 UTC |
Sawicki Mark WChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $12.79 | $0.00 |
DisclosureSEC source: 0001104659-23-100488 · tm2326093-1_4seq1.xml · derivative · entry 2 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,000 Underlying: Common Stock · 1,000 shares Expires 2029-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vested as part of an option that began vesting on the 1st of each month for forty-eight months beginning May 1, 2019. Read SEC document |
| September 12, 2023 Filed Sep 13, 2023 21:01 UTC |
Sawicki Mark WChief Scientific Officer
|
Exercise / conversionCommon Stock | 1,000 | $12.79 | $12,790.00 |
DisclosureSEC source: 0001104659-23-100488 · tm2326093-1_4seq1.xml · nonDerivative · entry 1 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: No Common Stock was sold by the reporting person in connection with the transactions disclosed on this Form 4. Read SEC document |
| September 06, 2023 Filed Sep 12, 2023 22:01 UTC |
Hariri Robert JDirector
|
SaleCommon Stock | 1,500 | $13.60 | $20,400.00 |
DisclosureSEC source: 0001104659-23-100116 · tm2325917d1_4seq1.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,516 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.